Atika Capital Management LLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Atika Capital Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $3.37 Million - $4.74 Million	-40,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$84.4 - $106.53 $1.94 Million - $2.45 Million	23,000 Added 135.29%	40,000 $3.45 Million
Q2 2019 Aug 12, 2019	SELL	$91.13 - $142.5 $911,300 - $1.43 Million	-10,000 Reduced 37.04%	17,000 $1.78 Million
Q1 2019 May 13, 2019	BUY	$103.48 - $143.84 $724,360 - $1.01 Million	7,000 Added 35.0%	27,000 $754,000
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $1.9 Million - $4.31 Million	20,000 New	20,000 $2.25 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.24B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.